Clinical trials for severe sepsis: Past failures, and future hopes

Infectious Disease Clinics of North America

Volumn 13, Issue 2, 1999, Pages 285-297

  Opal, S M ^a   Cross, A S ^a  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACTIVATED PROTEIN C; ANTISERUM; ANTITHROMBIN III; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BETA GLUCAN; BLOOD CLOTTING INHIBITOR; BRADYKININ ANTAGONIST; CENTOXIN; CORTICOSTEROID; ENDOTOXIN ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; IBUPROFEN; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; LISOFYLLINE; PHOSPHOLIPASE A2 INHIBITOR; POLYMYXIN B; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL MODEL; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFICACY; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; REVIEW; SEPTIC SHOCK;

EID: 0033054742     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70075-1     Document Type: Article

References (58)

1. E. Abraham A. Anzueto G. Gutierrez Double-blind, randomized, controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock Lancet 351 1998 929 933
2. E. Abraham M.P. Glauser T. Butler p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock JAMA 277 1997 1531 1534
3. E. Abraham R. Wunderink H. Silverman Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis syndrome, a randomized, controlled, double-blind multicenter clinical trial JAMA 273 1995 934 941
4. G.R. Bernard A.P. Wheeler J.A. Russell The effects of ibuprofen on the physiology and survival of patients with sepsis N Engl J Med 336 1997 912 918
5. R.C. Bone Gram-positive organisms in sepsis Arch Intern Med 154 1994 26 34
6. R.C. Bone Pathogenesis of sepsis Ann Intern Med 115 1991 457 469
7. R.C. Bone Sir Isaac Newton, sepsis, SIRS and CARS Crit Care Med 24 1996 1125 1129
8. R.C. Bone R.A. Balk F.B. Cerra Definitions for sepsis in organ failure and guidelines for the use of innovative therapies in sepsis Chest 101 1992 1644 1655
9. R.C. Bone R.A. Balk A.M. Fein A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial Crit Care Med 23 1995 994 1006
10. C. Brun-Buisson F. Doyon J. Carlet Incidence, risk factors, and outcome of severe sepsis and septic shock in adults, a multicenter, prospective study in intensive care units JAMA 274 1995 968 974
11. M.S. Chaussee J. Liu D.L. Stevens Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections J Infect Dis 173 1996 901 908
12. M.G. Cleveland J.D. Gorham T.L. Murphy Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway Infect Immun 164 1996 1906 1912
13. J. Cohen J. Carlet INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis Crit Care Med 24 1996 1431 1440
14. L. Cronin D.J. Cook J. Carlet Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature Crit Care Med 23 1995 1430 1439
15. A.S. Cross S.M. Opal Therapeutic intervention in sepsis with antibody to endotoxin: Is there a future? Journal of Endotoxin Research 1 1994 57 69
16. A.S. Cross S.M. Opal J.C. Sadoff Choice of bacteria in animal models of sepsis Infect Immun 61 1993 2741 2747
17. P. Damas D. Ledoux M. Nys Cytokine serum levels during severe sepsis in humans, IL-6 as a marker of severity Ann Surg 215 1992 356 362
18. R.L. Danner R.J. Elin J.M. Rosseini Endotoxemia in human septic shock Chest 99 1991 169 175
19. S.J. DeKimpe M. Kengatharan C. Thiemermann The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure Proc Natl Acad Sci U S A 92 1995 10359 10363
20. R.P. Dellinger J. Zimmerman S.M. Opal From the bench to the bedside: The future of sepsis research. Executive summary of the American College of Chest Physicians. National Institute of Allergy and Infectious Diseases, and National Heart, Lung, and Blood Institute Workshop Chest 111 1997 744 753
21. Dhainaut J.-F. A. Tenaillon J. LeTulzo Platelet activity factor antagonist BN52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled multicenter trial Crit Care Med 22 1994 1720 1728
22. C.A. Dinarello J.A. Gelfand S.M. Wolff Anticytokine strategies in the treatment of systemic inflammatory response syndrome JAMA 269 1993 1825 1835
23. E. Faist C. Kim Therapeutic immunomodulatory approaches for the control of systemic inflammatory response syndrome and the prevention of sepsis New Horiz 6 suppl 2 1998 97 102
24. A.M. Fein G.R. Bernard G.J. Criner Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, Deltibant (CP-0127) JAMA 277 1997 482 487
25. C.J. Fisher J.M. Agosti S.M. Opal Treatment of septic with the tumor necrosis factor receptor:Fc fusion protein N Engl J Med 334 1996 1697 1702
26. D. Gendrel M. Assicot J. Raymond Procalcitonin as a marker for the early diagnosis of neonatal infection J Pediatr 128 1996 570 573
27. J.E. Grau D.N. Maennel TNF inhibition and sepsis—sounding a cautionary note Nat Med 3 1997 1193 1195
28. Grover R. Lopez A. Lorente J. Multicenter, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock Crit Care Med 27 1999 A33
29. C.A. Hack M. Hart van Schijndel R.J. Interleukin-8 in sepsis: Relation to shock and inflammatory mediators Infect Immun 60 1992 2835 2839
30. W.A. Knaus F.E. Harrell Fisher C.J. Jr The clinical evaluation of new drugs for sepsis JAMA 270 1993 1233 1241
31. M. Kotb Bacterial pyrogenic exotoxins as superantigens Clin Microbiol Rev 8 1995 411 426
32. W.J. Kox R.C. Bone D. Krausch Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. New approach: Proof of principle Arch Intern Med 157 1997 389 393
33. A.M. Krieg An innate defense mechanism based on recognition of CpG motifs in microbial DNA J Lab Clin Med 128 1996 128 136
34. R.V. McCloskey R.C. Straube Sanders C. for the CHESS Trial Study Group Treatment of septic shock with human monoclonal antibody HA1A: Randomized, double-blind, placebo-controlled trial Ann Intern Med 120 1994 1 5
35. D.C. Morrison J.L. Ryan Endotoxin and disease mechanisms Annual Reviews of Medicine 38 1987 417 432
36. Nadel S, Derkx B, Hazelzet J, et al: A randomised placebo-controlled, sequential trial to study the efficacy of HA-1A human monoclonal antibody in children with meningococcal septic shock [abstract]. Presented at the Annual Meeting of the Royal College of Paediatrics and Child Health, York, 1997
37. C. Natanson W.D. Hoffman A.F. Suffredini Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis Ann Intern Med 120 1994 771 783
38. A. Oberhalzer U. Steckholzer H. Okamura Increased circulating levels of interleukin-18 during severe sepsis in humans Surg Forum 1998 88 90
39. S.M. Opal Lessons learned from clinical trials of sepsis J Endotoxin Res 2 1995 221 226
40. S.M. Opal New strategies in the management of sepsis Biomed Prog 11 1998 52 56
41. S.M. Opal Sepsis Sci Am Med 7 30 1998 1 17
42. Opal SM, Cohen J: Clinical gram-positive sepsis: Does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med, in press
43. S.M. Opal A.S. Cross J.W. Jhung Potential hazards of combination immunotherapy in the treatment of experimental septic shock J Infect Dis 173 1996 1415 1421
44. S.M. Opal C.J. Fisher J.P. Pribble The confirmatory interleukin-1 receptor antagonist trial in sepsis: A phase III randomized, double-blind, placebo-controlled, multicenter trial Crit Care Med 25 1997 1115 1124
45. S.M. Opal R. Yu Anti-endotoxin strategies for the prevention and treatment of septic shock Drugs 55 1998 497 508
46. G. Pilz R. Appel E. Kreuzer Comparison of early IgM-enriched immunoglobulin versus polyvalent IgG administration in score identified post–cardiac surgical patients at high risk for sepsis Chest 111 1997 419 426
47. D. Pittet B. Thiévent R.P. Wenzel Importance of preexisting comorbidities for prognosis of septicemia in critically ill patients Intensive Care Med 19 1993 265 272
48. 2 propeptide in acute lung injury Lancet 344 1994 1472 1474
49. K. Reinhart C. Wiegand-Löhnert F. Grimminger Assessment of the safety and efficacy of the monoclonal anti–tumor necrosis factor antibody-fragment, MAK195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study Crit Care Med 24 1996 733 742
50. E.T. Rietschel H. Brade O. Holst Bacterial endotoxin: Chemical composition, biological recognition, host response, and immunological detoxification Curr Top Microbiol Immunol 216 1996 39 46
51. S. Sriskandan D. Moyes J. Cohen Detection of circulating bacterial superantigen and lymphotoxin alpha in patients with streptococcal toxic-shock syndrome Lancet 348 1996 1315 1316
52. F. Stüber M. Petersen F. Bokalmann A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis Crit Care Med 24 1996 281 384
53. Van Deuren M. Van der Ven-Jongekrijg J. P.N.M. DeMacker Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections J Infect Dis 169 1994 157 161
54. Vincent J.-L. Search for effective immunomodulating strategies against sepsis Lancet 351 1998 922 923
55. Zedler S, Bone RC, Baue AE, et al: T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med, in press
56. F. Zeni B. Freeman C. Natanson Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment Crit Care Med 25 1997 1095 1100
57. Ziegler E.J. Fisher C.J. Jr C.L. Sprung Treatment of gram-negative bacteremia and septic shock with HA1A human monoclonal antibody against endotoxin N Engl J Med 324 1991 429 436
58. E.J. Ziegler J.A. McCutchan J. Fierer Treatment of gram-negative bacteremia and shock with human antiserum to a mutant, Escherichia coli N Engl J Med 307 1982 1225 1230